---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-023484"
form_type: "8-K"
ticker: "ELAN"
cik: "0001739104"
company_name: "Elanco Animal Health Inc"
filed_at: "2023-02-21T23:59:59+00:00"
generated_at: "2026-06-19T07:09:17.157318+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Elanco Q4 revenue $988M (-11% YoY), full year net loss $74M; guides FY2023 revenue $4.28-4.4B

## Summary
- Q4 revenue $988M (-11% reported, -6% CER); Pet Health $423M (-14%), Farm Animal $552M (-9%).
- Q4 reported net loss $54M ($0.11 loss per share); adjusted net income $95M, adjusted EPS $0.19.
- Full year 2022 revenue $4,418M (-7% reported); reported net loss $74M; adjusted EBITDA $1,023M (23.2% margin).
- FY2023 guidance: revenue $4,280-4,400M; adjusted EBITDA $920-1,000M; adjusted EPS $0.74-0.83.
- Initiated JAK inhibitor submission to FDA; received FDA approval for Bexacat (feline diabetes); EPA approval for Advantage/K9 Advantix relaunch; Bovaer launch expected H1 2024.

## SEC filing metadata
- accession: 0001104659-23-023484
- form_type: 8-K
- ticker: ELAN
- cik: 0001739104
- company_name: Elanco Animal Health Inc
- filed_at: 2023-02-21T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739104/000110465923023484/0001104659-23-023484-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739104/000110465923023484/tm237362d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-023484
- JSON: https://secwatch.observer/filing/0001104659-23-023484.json
- Plain text: https://secwatch.observer/filing/0001104659-23-023484.txt

## Key facts
- Earnings Releases
  Elanco Animal Health Inc updated its the full year and fiscal quarter ended December 31, 2022 guidance (initiated).
  - Period: the full year and fiscal quarter ended December 31, 2022
  - Guidance: initiated
  - Result: reported results
  source text: Attached as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated February 21, 2023, announcing the results of operations for the full year and fiscal quarter ended December 31, 2022 and guidance for the full year and first half of 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739104/000110465923023484/0001104659-23-023484-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.